FindTrial
Sign In

LY2140023

DRUG18 trials

Sponsors

Denovo Biopharma LLC, Eli Lilly and Company

Conditions

Healthy ParticipantsHealthy SubjectsHealthy Volunteer StudyHealthy VolunteersHepatic InsufficiencySchizophreniaSchizophrenic Disorders

Phase 1

A Study of Safety and Tolerability in Subjects With Schizophrenia
CompletedNCT01354353
Denovo Biopharma LLCSchizophrenia
Start: 2011-05-31End: 2012-03-31Updated: 2022-09-14
The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects
CompletedNCT01440478
Eli Lilly and CompanyHealthy Subjects
Start: 2011-09-30End: 2011-10-31Target: 30Updated: 2011-10-12
A Study of LY2140023 in Hepatically-Impaired Participants
CompletedNCT01475136
Denovo Biopharma LLCHepatic Insufficiency
Start: 2011-11-30End: 2012-12-31Updated: 2021-09-22
A Study of LY2979165 and LY2140023 in Healthy Volunteers
CompletedNCT01524237
Eli Lilly and CompanyHealthy Volunteers
Start: 2012-04-30End: 2013-07-31Target: 52Updated: 2013-08-02
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
CompletedNCT01606436
Denovo Biopharma LLCSchizophrenic Disorders
Start: 2012-06-30End: 2012-09-30Updated: 2023-04-03
A Study of LY2140023 in Healthy Participants
CompletedNCT01609218
Denovo Biopharma LLCHealthy Volunteer Study
Start: 2012-06-30End: 2012-09-30Updated: 2021-09-21
A Study of LY2140023 in Healthy Participants
CompletedNCT01637142
Denovo Biopharma LLCHealthy Participants
Start: 2012-07-31End: 2012-07-31Updated: 2021-09-21
A Study of LY2140023 in Healthy Participants
WithdrawnNCT01659177
Denovo Biopharma LLCHealthy Participants
Start: 2012-08-31End: 2012-09-30Updated: 2021-08-23

Phase 2

Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
CompletedNCT00149292
Denovo Biopharma LLCSchizophrenia
Start: 2005-08-23End: 2006-07-17Updated: 2021-08-20
A Study for Patients With Schizophrenia
CompletedNCT00520923
Eli Lilly and CompanySchizophrenia
Start: 2007-09-30End: 2008-10-31Updated: 2009-10-19
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
CompletedNCT00845026
Denovo Biopharma LLCSchizophrenia
Start: 2009-03-31End: 2010-12-31Updated: 2022-11-08
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
CompletedNCT01052103
Denovo Biopharma LLCSchizophrenia
Start: 2010-01-31End: 2012-06-30Updated: 2022-09-07
A Study in Schizophrenia Patients
CompletedNCT01086748
Eli Lilly and CompanySchizophrenia
Start: 2010-03-31End: 2012-05-31Target: 880Updated: 2012-09-25
A Study in Schizophrenic Patients
TerminatedNCT01125358
Denovo Biopharma LLCSchizophrenia
Start: 2010-05-31End: 2012-09-30Updated: 2021-09-14
A Long-Term, Open-Label, Study on Schizophrenia
TerminatedNCT01129674
Eli Lilly and CompanySchizophrenia
Start: 2010-06-30End: 2012-10-31Target: 1210Updated: 2013-01-21

Phase 3

A Study of LY2140023 in Patients With Schizophrenia
TerminatedNCT01307800
Denovo Biopharma LLCSchizophrenia
Start: 2011-03-31End: 2012-09-30Updated: 2022-10-18
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
TerminatedNCT01328093
Denovo Biopharma LLCSchizophrenia
Start: 2011-04-30End: 2012-10-31Updated: 2022-09-07
A Physical Dependence Study in Schizophrenia
CompletedNCT01452919
Denovo Biopharma LLCSchizophrenia
Start: 2011-11-30End: 2012-09-30Updated: 2022-09-14

Related Papers

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
2014-12-1086 citations
Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
Schizophrenia Research and Treatment2014-01-0175 citations